Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-01-01
2008-01-01
Maier, Leigh C. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S054000, C514S063000, C623S001430
Reexamination Certificate
active
07314860
ABSTRACT:
The present invention is related to heparin-like compounds characterized by their capacity of inhibiting collagen-induced platelet aggregation in flowing whole blood and their use for prophylactic treatment of arterial thrombosis associated with vascular or microvascular injury and interventions. Said properties are related to a high coupling density of negatively charged heparin or heparin-like glycosaminoglycan molecules, present in multiple heparin or heparin-like glycosaminoglycans as well as in proteoglycans containing said multiple heparin or heparin-like glycosaminoglycans or lower-molecular-weight heparin or heparin-like glycosaminoglycans connected directly or through spacer/linker molecules to globular core molecules. Heparin-like compounds, with said properties are obtainable from mammalian mast cells, by tissue extraction or cell cultivation. The heparin-like compounds of the present invention can also be produced by synthetical, semisynthetical and/or biotechnological methods and they are useful for manufacturing preparations, means and devices for local or topical application in prophylactic treatment of arterial thrombosis and its sequelae.
REFERENCES:
patent: 4265927 (1981-05-01), Ericksson et al.
patent: 4350629 (1982-09-01), Yannas et al.
patent: 4863907 (1989-09-01), Sakurai
patent: 5019393 (1991-05-01), Ito et al.
patent: 5041292 (1991-08-01), Feijen
patent: 5071973 (1991-12-01), Keller et al.
patent: 5162430 (1992-11-01), Rhee et al.
patent: 5510418 (1996-04-01), Rhee et al.
patent: 5529986 (1996-06-01), Larsson et al.
patent: 5571166 (1996-11-01), Dinh et al.
patent: 5618298 (1997-04-01), Simon
patent: 5643580 (1997-07-01), Subramaniam
patent: 5702754 (1997-12-01), Zhong
patent: 5851230 (1998-12-01), Weadock et al.
patent: 5869127 (1999-02-01), Zhong
patent: 5876433 (1999-03-01), Lunn
patent: 0 341 006 (1989-11-01), None
patent: 0 454 599 (1991-10-01), None
patent: 89/05646 (1989-06-01), None
patent: 91/15252 (1991-10-01), None
patent: 93/05074 (1993-03-01), None
patent: 93/06836 (1993-04-01), None
patent: 97/19701 (1997-06-01), None
Schurmann, K. et al “Iliac arteries: plain and heparin-coated . . . ” Radiology (1997) vol. 203, pp. 55-60.
Fram, D. et al “Local delivery of heparin to balloon angoiplasty sites . . . ” Cath. Cardiovasc. Diag. (1997) vol. 41, pp. 275-286.
Suzuki, S. et al “Glycosaminoglycan chains of preoteoglycans . . . ” Pure Appl. Chem. (1991) vol. 63, No. 4, pp. 545-554.
Serruys, P. et al “Heparing-coated Palmaz-Schatz stents in human coronary arteries . . . ” Circulation (1996) vol. 93, No. 3, pp. 412-422.
Lindstedt et al., “Soluble Heparin Proteoglycans . . . ”, J. Lipid Res., 1992, pp. 65-75, vol. 33, Stanford University Libraries' HighWire Press, Stanford, California, USA.
Messmore et al., “In Vitro Studies of the Interaction of Heparin, Low Molecular Weight Heparin and Heparinoids with Platelete”, from Heparin and Related Polysaccharides—Structures and Activities, ed. OFOSU, p. 21, NY Acad of Sci, New York, New York, USA.
Mattsson et al , “Antithrombotic Effects of Heparin Oligosaccharides”, from Heparin and Related Polysaccharides—Structures and Activities, ed. OFOSU, pp. 323-332, NY Acad of Sci, New York, New York, USA.
Hardhammer et al., “Reduction in Thrombotic Events with Heparin-Coated Palmaz-Schatz Stents in Normal Porcine Coronary Stents”, Circulation, 1996, pp. 423-430, vol. 93, No. 3, Stanford University Libraries' HighWire Press, Stanford, California, USA.
De Scheerder et al., “Experimental Study of Thrombogenicity and Foreign Body Reaction Induced by Heparin-Coated Coronary Stents”, Circulation, 1997, pp. 1549-1553, vol. 95, No. 6, Stanford University Libraries' HighWire Press, Stanford, California, USA.
Nader, “Characterization of a Heparin Sulfate and a Peculiar Chrondroitin 4-Sulfate Proteoglycan from Platelets”, The Journal of Biological Chemistry, 1991, pp. 10518-10523, vol. 266, No. 16, American Society for Biochemistry and Molecular Biology, Bethesda, Maryland, USA.
Sobel et al., “Heparin Inhibition of vonWillebrand Factor-Dependent Platelet-Function In Vitro and In Vivo”, Journal of Clinical Investigation, 1991, pp. 1787-1793, vol. 87, No. 5, Stanford University Libraries' HighWire Press, Stanford, California, USA.
Lassila et al., “Native Macromolecular Heparin Proteoglycans Exocytosed from Stimulated Rat Sterosal Mast Cells Strongly Inhibit Platelet-Collagen Interactions”, Arteriosclerosis Thrombosis and Vascular Biology, 1997, pp. 3578-3587, vol. 17, No. 12, Stanford University Libraries' HighWire Press, Stanford, California, USA.
Riitta Lassila, et al., “Native Macromolecular Heparin Proteoglycans Exocytosed From Stimulated Rat Serosal Mast Cells Strongly Inhibit Platelet-Collagen Interactions”, Arteriosclerosis, Thrombasis, and Vascular Biology, pp. 19-28, vol. 17, No. 12, Dec. 1997.
“Dorland's Illustrated”, 27thEdition Medical Dictionary, p. 1165, W.B. Saunders Company, Harcourt Brace Jovanovich, Inc.
Rothenberg et al., “Influence of the Fibroblast Environment on the Structure of Mast Cell Proteoglycans” in Heparin and Related Polysaccharides, ed. OFOSU, 1989, pp. 233-244.
Schurmann et al., “Iliac Arteries: Plain and Heparin-Coated Dacron-Covered Stent-Grafts Compared with Noncovered Metal Stents—An Experimental Study”, Radiology, 1997, pp. 55-63, vol. 203, No. 1, Stanford University Libraries' HighWire Press, Stanford, California, USA.
Ritter et al., “Heparin Coating of Vascular Prostheses Reduces Thromboemboli”, Surgery, 1997, pp. 888-892, vol. 122, No. 5, Elsevier Science, London, England.
The Merck Index (12thEdition), Entry 4685, 1996.
Moczar et al., “Biocompatibility of a Vascular Substitute from Heparinized Human Umbilical Cord Vein”, Life Support System, 1986, pp. 103-105, vol. 4, Suppl. 2.
Ip et al., “Patency of Heparin-PVA Coated Tubes at Low Flow Rates”, Biomaterials, 1989, pp. 313-317, vol. 10, No. 5, Elsevier Science, London, England.
Kovanen Petri
Lassila Riitta
Lindstedt Ken
Buchanan & Ingersoll & Rooney PC
Jenny Ja Antti Wilhurin Rahasto
Maier Leigh C.
LandOfFree
Heparin-like compounds, their preparation and use to prevent... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heparin-like compounds, their preparation and use to prevent..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heparin-like compounds, their preparation and use to prevent... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2806145